Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with Surrozen, a biotech company developing tissue-specific antibodies that have the potential to regenerate tissue in situations of serious diseases.

Under the terms of the agreement, BLB will provide cutting-edge research services to enhance the characterization of regenerative pathways in chronic liver disease.

BLB aims at providing valuable insights into complex disease pathways and drug responses in a more meaningful liver disease pre-clinical context. For more information please visit www.liver.barcelona